Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 101Endometrial Neoplasms 74Uterine Cervical Neoplasms 63Carcinoma, Non-Small-Cell Lung 56Colorectal Neoplasms 50Melanoma 49Triple Negative Breast Neoplasms 42Carcinoma, Renal Cell 41Stomach Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Fallopian Tube Neoplasms 33Breast Neoplasms 33Pancreatic Neoplasms 27Neoplasms 25Esophageal Neoplasms 24Carcinoma, Transitional Cell 24Neoplasm Metastasis 23Carcinoma, Hepatocellular 20Lung Neoplasms 19Carcinoma, Ovarian Epithelial 19Small Cell Lung Carcinoma 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 17Prostatic Neoplasms 14Cholangiocarcinoma 13Carcinoma, Merkel Cell 11Kidney Neoplasms 10Mesothelioma 9Uterine Neoplasms 8

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × pembrolizumab × Gynecologic × Clear all
NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT06046274 2024-04-30

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Genmab

Phase 2 Withdrawn
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡